2026-06-14T05:05:34Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/97702025-06-09T07:29:48Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19609

00925njm 22002777a 4500 dc Kissling, Esther author Valenciano, Marta author Pozo Sanchez, Francisco author Vilcu, Ana-Maria author Reuss, Annicka author Rizzo, Caterina author Larrauri, Amparo author Horváth, Judit Krisztina author Brytting, Mia author Domegan, Lisa author Korczyńska, Monika author Meijer, Adam author Machado, Ausenda author Ivanciuc, Alina author Višekruna Vučina, Vesna author van der Werf, Sylvie author Schweiger, Brunhilde author Bella, Antonino author Gherasim, Alin Manuel author Ferenczi, Annamária author Zakikhany, Katherina author O Donnell, Joan author Paradowska-Stankiewicz, Iwona author Dijkstra, Frederika author Guiomar, Raquel author Lazar, Mihaela author Kurečić Filipović, Sanja author Johansen, Kari author Moren, Alain author 2018 BACKGROUND: During the 2015/16 influenza season in Europe, the cocirculating influenza viruses were A(H1N1)pdm09 and B/Victoria, which was antigenically distinct from the B/Yamagata component in the trivalent influenza vaccine. METHODS: We used the test-negative design in a multicentre case-control study in twelve European countries to measure 2015/16 influenza vaccine effectiveness (VE) against medically attended influenza-like illness (ILI) laboratory-confirmed as influenza. General practitioners swabbed a systematic sample of consulting ILI patients and a random sample of influenza-positive swabs was sequenced. We calculated adjusted VE against influenza A(H1N1)pdm09, A(H1N1)pdm09 genetic group 6B.1 and influenza B overall and by age group. RESULTS: We included 11 430 ILI patients, of which 2272 were influenza A(H1N1)pdm09 and 2901 were influenza B cases. Overall VE against influenza A(H1N1)pdm09 was 32.9% (95% CI: 15.5-46.7). Among those aged 0-14, 15-64 and ≥65 years, VE against A(H1N1)pdm09 was 31.9% (95% CI: -32.3 to 65.0), 41.4% (95% CI: 20.5-56.7) and 13.2% (95% CI: -38.0 to 45.3), respectively. Overall VE against influenza A(H1N1)pdm09 genetic group 6B.1 was 32.8% (95% CI: -4.1 to 56.7). Among those aged 0-14, 15-64 and ≥65 years, VE against influenza B was -47.6% (95% CI: -124.9 to 3.1), 27.3% (95% CI: -4.6 to 49.4) and 9.3% (95% CI: -44.1 to 42.9), respectively. CONCLUSIONS: Vaccine effectiveness (VE) against influenza A(H1N1)pdm09 and its genetic group 6B.1 was moderate in children and adults, and low among individuals ≥65 years. Vaccine effectiveness (VE) against influenza B was low and heterogeneous among age groups. More information on effects of previous vaccination and previous infection is needed to understand the VE results against influenza B in the context of a mismatched vaccine. Influenza Other Respir Viruses. 2018 Jul;12(4):423-437. 10.1111/irv.12520 1750-2659 1750-2640 Influenza and other respiratory viruses 29125681 http://hdl.handle.net/20.500.12105/9770 Case-control study Influenza Influenza vaccine Multicentre study Vaccine effectiveness 2015/16 I-MOVE/I-MOVE+ multicentre case-control study in Europe: Moderate vaccine effectiveness estimates against influenza A(H1N1)pdm09 and low estimates against lineage-mismatched influenza B among children